Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Johns Hopkins researchers believe they may have discovered an explanation for the sleepless nights associated with restless legs syndrome (RLS), a symptom that persists even when the disruptive, overwhelming nocturnal urge to move the legs is treated successfully with medication.
Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a University at Buffalo professor who is conducting research on a drug that is showing success treating pregnant women with this condition.
Cavalier King Charles with neuropathic pain induced by a condition characterized by a brain–skull size mismatch do not show significant improvement after nonsurgical treatment for the condition, indicate UK study results.
Depomed, Inc. today reported financial results for the quarter and nine months ended September 30, 2012.
XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).
Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults.
Five recent Johns Hopkins University School of Nursing DNP graduates have taken different and unique approaches in working to improve the implementation of pain management in hospitals and clinical practices.
Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.
Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.
Depomed, Inc. today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes.
XenoPort, Inc. announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.
Depomed, Inc. today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN).
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Depomed, Inc. today announced that it has acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.
GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.
Chronic pain, by definition, is difficult to manage, but a new study by UCSF scientists shows how a cell therapy might one day be used not only to quell some common types of persistent and difficult-to-treat pain, but also to cure the conditions that give rise to them.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The latest American Academy of Neurology/American Headache Society Guidelines released this week outline evidence-based and effective treatments that can prevent migraine attacks and lessen their severity.
Botox injections have been used in prevention of migraines but new research shows that its effect is only modest. Among chronic sufferers who had at least 15 migraines a month, the treatment prevented, on average, about two headaches a month. Botox was no more effective than some of the most widely prescribed drugs used for migraines when the treatments were compared.
Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana.